USANA Health Sciences, Inc. released its financial report for Q4 and full year fiscal 2022. The company’s fourth quarter net sales were $228 million, down 15% from the prior year’s quarter, while full year net sales were $999 million, a 16% decline over 2021. Active customers were down 13% for the year to 490,000.
Asia Pacific continues to be a strong region for the company with $183 million in Q4 net sales and 384,000 active customers. The Americas and Europe represented $45 million in Q4 net sales with 106,000 active customers.
Fiscal 2022 diluted EPS was $3.59, down from $5.73 in 2021. Overall, USANA generated $104 million of operating cash flow in 2022 and ended the year with $288 million in cash and cash equivalents with zero debt.
“While 2022 presented a challenging operating environment for both USANA and our industry, we remained focused on executing our long-term growth strategy,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “In 2022, we made progress in several areas that position USANA for future growth. These areas include digital commerce initiatives to support our business, new market expansion, the launch of our affiliate program in select markets, and the completion of two acquisitions. These activities further our efforts to differentiate and diversify our business while contributing to shareholder returns.”
The company reaffirmed its fiscal 2023 net sales and diluted EPS outlook of $850 million-$950 million and $2.35-$3.30 respectively.
